Arcutis Biotherapeutics’ (ARQT) Buy Rating Reiterated at Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) in a research report report published on Wednesday morning, Marketbeat.com reports. Needham & Company LLC currently has a $20.00 price objective on the stock. A number of other equities analysts also recently commented on ARQT. Guggenheim reiterated a […]
More Stories
North Korean Media Says US-South Korea Submarine Deal Will Spark ‘Hot Arms Race’
By Guy Birchall North Korea’s state media said on Nov. 18 that South Korea’s U.S.-approved plan to build nuclear-powered submarines...
Zelenskyy Says He Will Meet Trump on Sunday to Discuss Peace Plan
By Tom Ozimek Ukrainian President Volodymyr Zelenskyy said on Dec. 26 that he will meet President Donald Trump in Florida...
Death Penalty Possible for Suspect in DC Shooting After New Federal Charges
By Bill Pan Rahmanullah Lakanwal, the man accused of killing a National Guard member and severely wounding another in an...
US Dollar Poised for Largest Annual Decline Since 2003
By Andrew Moran While the so-called Santa Claus rally delivered year-end gains for stocks and precious metals, the U.S. dollar...
The Good News of Economic Growth
By Jeffrey A. Tucker The Trump administration received some very welcome news in the form of third-quarter economic growth. Even...
Taiwan Gets Dec. 25 Off for First Time in Over 2 Decades
By Lily Zhou Residents of Taiwan got Dec. 25 off for the first time in nearly 25 years after lawmakers...